NCT05414500 2026-04-09Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis FungoidesUniversity of Alabama at BirminghamPhase 1 Recruiting10 enrolled
NCT04848064 2026-02-10Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Recruiting12 enrolled